The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
Level | Code | Title | |
---|---|---|---|
1 | H | Systemic hormonal preparations, excl. Sex hormones and insulins | |
2 | H01 | Pituitary and hypothalamic hormones and analogues | |
3 | H01C | Hypothalamic hormones | |
4 | H01CC | Anti-gonadotropin-releasing hormones |
Code | Title | |
---|---|---|
H01CC01 | Ganirelix | |
H01CC02 | Cetrorelix | |
H01CC03 | ||
H01CC04 | ||
H01CC53 | ||
H01CC54 |
Active Ingredient | Description | |
---|---|---|
Cetrorelix |
Cetrorelix is a synthetic decapeptide with gonadotropin-releasing hormone (GnRH) antagonistic activity. GnRH induces the production and release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the gonadotrophic cells of the anterior pituitary. Due to a positive estradiol (E2) feedback at midcycle, GnRH liberation is enhanced resulting in an LH-surge. This LH-surge induces the ovulation of the dominant follicle, resumption of oocyte meiosis and subsequently luteinization as indicated by rising progesterone levels. Cetrorelix competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. Cetrorelix binds to the gonadotropin releasing hormone receptor and acts as a potent inhibitor of gonadotropin secretion. It competes with natural GnRH for binding to membrane receptors on pituitary cells and thus controls the release of LH and FSH in a dose-dependent manner. Cetrotide (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. |
|
Elagolix |
Elagolix is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of elagolix results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone. |
|
Ganirelix |
Ganirelix is a GnRH antagonist, which modulates the hypothalamic-pituitary-gonadal axis by competitive binding to the GnRH receptors in the pituitary gland. As a result a rapid, profound, reversible suppression of endogenous gonadotrophins occurs, without initial stimulation as induced by GnRH agonists. |
|
Linzagolix |
Linzagolix is a selective, non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist that inhibits endogenous GnRH signalling by binding competitively to GnRH receptors in the pituitary gland, thereby modulating the hypothalamic-pituitary-gonadal axis. |
Title | Information Source | Document Type | |
---|---|---|---|
CETROTIDE Powder and solvent for solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
FYREMADEL Solution for injection in pre-filled syringe | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC | |
ORGALUTRAN Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC | |
ORILISSA Film-coated tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
RYEQO Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
YSELTY Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |